TGF-β / Smad Signaling
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
- A8692 PF-431396Summary: Pyk2 and FAK inhibitor
- A8801 ICP 103Summary: Protein kinase inhibitor
- A8812 PD173955Target: Bcr-Abl|SrcSummary: Dual Src/Abl kinase inhibitor, ATP-competitive,
- B2286 K02288Target: ALKSummary: ALK inhibitor
- B1176 Y-39983 dihydrochlorideSummary: ROCK family inhibitor
- B1293 Y-276329 CitationTarget: ROCKSummary: ROCK inhibitor,potent and selective
- B1011 Bafetinib (INNO-406)2 CitationSummary: Bcr-Abl/Lyn tyrosine kinase inhibitor
- B1404 DCC-2036 (Rebastinib)Target: FLT3|Bcr-Abl|Tie-2|KDRSummary: Bcr-Abl inhibitor
- B1294 SR-3677Target: ROCKSummary: Rho Kinase (ROCK-II) inhibitor
- C4877 1,2-Distearoyl-sn-glycerol